NICE opts to reject Acorda’s MS drug Fampyra
The MS Society responds as MS therapy Fampyra is rejected
Read Moreby John Pinching | Jun 22, 2022 | News | 0
The MS Society responds as MS therapy Fampyra is rejected
Read Moreby Selina McKee | Apr 14, 2020 | News | 0
Biogen’s Famprya, Sanofi’s Suliqua, Janssen’s Stelara and Shionogi Rizmoic will be funded on the NHS in Scotland
Read Moreby Selina McKee | Nov 13, 2018 | News | 0
A medicine used to treat a rare cancer that predominantly occurs in very young children is to be routinely funded on the NHS in Scotland.
Read Moreby Selina McKee | May 24, 2017 | News | 0
Biogen’s Fampyra has been granted a standard approval by European regulators on the back of late-stage data supporting its use to improve walking in patients with multiple sclerosis.
Read Moreby Selina McKee | Nov 7, 2016 | News | 0
The Scottish Medicines Consortium has endorsed the use of five new therapies by NHS Scotland to treat melanoma, ovarian cancer, hepatitis C, Fabry disease and bacterial vaginosis.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
